335 related articles for article (PubMed ID: 27262709)
41. A Comparative Retrospective Study of Immunotherapy RANO
Chen X; Lim-Fat MJ; Qin L; Li A; Bryant A; Bay CP; Gao L; Miskin N; Liu Z; Iorgulescu JB; Xu X; Reardon DA; Young GS
Front Oncol; 2021; 11():679331. PubMed ID: 34249718
[TBL] [Abstract][Full Text] [Related]
42. Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.
Duerinck J; Du Four S; Sander W; Van Binst AM; Everaert H; Michotte A; Hau P; Neyns B
Anticancer Res; 2015 Oct; 35(10):5551-7. PubMed ID: 26408725
[TBL] [Abstract][Full Text] [Related]
43. Introduction of a standardized multimodality image protocol for navigation-guided surgery of suspected low-grade gliomas.
Mert A; Kiesel B; Wöhrer A; Martínez-Moreno M; Minchev G; Furtner J; Knosp E; Wolfsberger S; Widhalm G
Neurosurg Focus; 2015 Jan; 38(1):E4. PubMed ID: 25552284
[TBL] [Abstract][Full Text] [Related]
44. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.
Chinot OL; Macdonald DR; Abrey LE; Zahlmann G; Kerloëguen Y; Cloughesy TF
Curr Neurol Neurosci Rep; 2013 May; 13(5):347. PubMed ID: 23529375
[TBL] [Abstract][Full Text] [Related]
45. How treatment monitoring is influencing treatment decisions in glioblastomas.
Neagu MR; Huang RY; Reardon DA; Wen PY
Curr Treat Options Neurol; 2015 Apr; 17(4):343. PubMed ID: 25749847
[TBL] [Abstract][Full Text] [Related]
46. RANO 2.0: The revised Response Assessment in Neuro-Oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future.
Wen PY; van den Bent M; Vogelbaum MA; Chang SM
Neuro Oncol; 2024 Jan; 26(1):2-4. PubMed ID: 37774741
[No Abstract] [Full Text] [Related]
47. Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
Cooney TM; Cohen KJ; Guimaraes CV; Dhall G; Leach J; Massimino M; Erbetta A; Chiapparini L; Malbari F; Kramer K; Pollack IF; Baxter P; Laughlin S; Patay Z; Young Poussaint T; Warren KE
Lancet Oncol; 2020 Jun; 21(6):e330-e336. PubMed ID: 32502459
[TBL] [Abstract][Full Text] [Related]
48. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
49. Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.
Vollmuth P; Foltyn M; Huang RY; Galldiks N; Petersen J; Isensee F; van den Bent MJ; Barkhof F; Park JE; Park YW; Ahn SS; Brugnara G; Meredig H; Jain R; Smits M; Pope WB; Maier-Hein K; Weller M; Wen PY; Wick W; Bendszus M
Neuro Oncol; 2023 Mar; 25(3):533-543. PubMed ID: 35917833
[TBL] [Abstract][Full Text] [Related]
50. Management of low-grade gliomas: a review of patient-perceived quality of life and neurocognitive outcome.
Shields LB; Choucair AK
World Neurosurg; 2014; 82(1-2):e299-309. PubMed ID: 24560709
[TBL] [Abstract][Full Text] [Related]
51. Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
Lin NU; Lee EQ; Aoyama H; Barani IJ; Baumert BG; Brown PD; Camidge DR; Chang SM; Dancey J; Gaspar LE; Harris GJ; Hodi FS; Kalkanis SN; Lamborn KR; Linskey ME; Macdonald DR; Margolin K; Mehta MP; Schiff D; Soffietti R; Suh JH; van den Bent MJ; Vogelbaum MA; Wefel JS; Wen PY;
Lancet Oncol; 2013 Sep; 14(10):e396-406. PubMed ID: 23993384
[TBL] [Abstract][Full Text] [Related]
52. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.
Chukwueke UN; Wen PY
CNS Oncol; 2019 Mar; 8(1):CNS28. PubMed ID: 30806082
[No Abstract] [Full Text] [Related]
53. Pseudoprogression: relevance with respect to treatment of high-grade gliomas.
Fink J; Born D; Chamberlain MC
Curr Treat Options Oncol; 2011 Sep; 12(3):240-52. PubMed ID: 21594589
[TBL] [Abstract][Full Text] [Related]
54. Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.
Ou SH; Klempner SJ; Azada MC; Rausei-Mills V; Duma C
Lung Cancer; 2015 Jun; 88(3):355-9. PubMed ID: 25882777
[TBL] [Abstract][Full Text] [Related]
55. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.
Bolcaen J; Acou M; Boterberg T; Vanhove C; De Vos F; Van den Broecke C; Van Holen R; Deblaere K; Goethals I
Nucl Med Commun; 2017 Mar; 38(3):242-249. PubMed ID: 27984537
[TBL] [Abstract][Full Text] [Related]
56. Barriers to accrual and enrollment in brain tumor trials.
Lee EQ; Chukwueke UN; Hervey-Jumper SL; de Groot JF; Leone JP; Armstrong TS; Chang SM; Arons D; Oliver K; Verble K; Musella A; Willmarth N; Alexander BM; Bates A; Doherty L; Galanis E; Gaffey S; Halkin T; Friday BE; Fouladi M; Lin NU; Macdonald D; Mehta MP; Penas-Prado M; Vogelbaum MA; Sahebjam S; Sandak D; van den Bent M; Weller M; Reardon DA; Wen PY
Neuro Oncol; 2019 Sep; 21(9):1100-1117. PubMed ID: 31175826
[TBL] [Abstract][Full Text] [Related]
57. The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal.
Le Rhun E; Devos P; Boulanger T; Smits M; Brandsma D; Rudà R; Furtner J; Hempel JM; Postma TJ; Roth P; Snijders TJ; Winkler F; Winklhofer S; Castellano A; Hattingen E; Capellades J; Gorlia T; Van den Bent M; Wen PY; Bendszus M; Weller M;
Neuro Oncol; 2019 May; 21(5):648-658. PubMed ID: 30715514
[TBL] [Abstract][Full Text] [Related]
58. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort.
Le Rhun E; Devos P; Winklhofer S; Lmalem H; Brandsma D; Kumthekar P; Castellano A; Compter A; Dhermain F; Franceschi E; Forsyth P; Furtner J; Galldiks N; Gállego Pérez-Larraya J; Gempt J; Hattingen E; Hempel JM; Lukacova S; Minniti G; O'Brien B; Postma TJ; Roth P; Rudà R; Schaefer N; Schmidt NO; Snijders TJ; Thust S; van den Bent M; van der Hoorn A; Vogin G; Smits M; Tonn JC; Jaeckle KA; Preusser M; Glantz M; Wen PY; Bendszus M; Weller M
Neuro Oncol; 2022 Oct; 24(10):1726-1735. PubMed ID: 35157772
[TBL] [Abstract][Full Text] [Related]
59. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.
Arvold ND; Armstrong TS; Warren KE; Chang SM; DeAngelis LM; Blakeley J; Chamberlain MC; Dunbar E; Loong HH; Macdonald DR; Reardon DA; Vogelbaum MA; Yuan Y; Weller M; van den Bent M; Wen PY
Neuro Oncol; 2018 Jun; 20(7):897-906. PubMed ID: 29788429
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure.
Kazda T; Hardie JG; Pafundi DH; Kaufmann TJ; Brinkmann DH; Laack NN
J Neurooncol; 2015 Mar; 122(1):197-203. PubMed ID: 25577400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
